Even as the newly-listed Mankind Pharma shares took a breather on their second day on Dalal Street, the pharma and healthcare products company remained well among the country's top 100 most valuable companies. The stock of Mankind Pharma — whose popular products include Manforce condoms and Prega News pregnancy test kits — fell more than six per cent on Wednesday, but that did not force the company out of India's top 100 club in terms of market capitalisation (mcap) or market value. In fact, the company stays well among the top 90. 

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

At the current market price, of Rs 1,424.1 per share, Mankind Pharma's market value stands at Rs 57,045.8 crore, according to provisional exchange data. To put things into perspective, Mankind Pharma has a market cap larger than 14 of the country's biggest 100 companies, and four pharma companies combined. 

Here's a list of companies that lag the new kid on the block, Mankind Pharma, among the top 100:

Company CMP (in rupees per share) Mcap (in crore rupees)
Bosch 19,227.6 56,709
Torrent Pharma 1,649.4 55,819
PNB 50.3 55,374.4
Canara Bank 302.8 54,931.9
ICICI Lombard General Insurance Company 1,098.2 53,933.7
Indian Hotels 374.2 53,151.4
Zydus Lifesciences 524.7 53,110.4
UPL 694.6 53,070.6
Tube Investments of India 2,724.3 52,612
PI Industries 3,459.3 52,483.1
Zomato 60.9 52,281.6
Hero MotoCorp 2,591.8 51,793.5
Samvardhana Motherson International 75.9 51,445.6
Trent 1,432 50,904

ALSO READ: A stellar market debut for Manforce condom maker; shares finish listing day at 32% premium

Mankind Pharma's mcap even exceeds the total market cap of four pharma companies combined. These are: Granules India, Glenmark Pharma, Laurus Labs and Sanofi India. 

Company CMP (in rupees) Mcap (in crore rupees)
Granules India 301.5  7,297.6
Glenmark Pharma 570.5  16,100.5
Laurus 332.3  17,883.2
Sanofi 5,670 13,042
Total 54,323.3

The IPO of Mankind Pharma, the fourth largest drug maker in the country by domestic sales, is the first in the pharma space to have made money for investors since November 2021.

ALSO READ: Buy, sell or hold Mankind Pharma shares after stellar debut?

Mankind Pharma: A bumper listing following a long wait

The listing of Mankind Pharma is among the strongest over the recent years, and comparable with the IPOs and debuts of 2021 — a blockbuster year for the primary market that saw 66 mainstream initial share sales in total. 

On May 9, Mankind Pharma debuted on stock exchanges BSE and NSE at a premium of 20 per cent over the issue price, and finished the listing day at a premium of 32 per cent. 

Catch latest stock market updates here. For all other news related to business, politics, tech, sports and auto, visit Zeebiz.com.